The gene therapy developer has boosted its initial public offering, which gave an exit to Alexandria Real Estate Equities, to more than $163m in size.

Stoke Therapeutics, a genetic disease therapy developer backed by life sciences real estate developer Alexandria Real Estate Equities, closed its initial public offering at just over $163m on Friday.

The offering initially raised about $142m when Stoke priced its shares at $18.00 on Wednesday last week. However, its share price closed at $26.00 on Thursday and had reached $27.29 by the time the Nasdaq Global Select Market closed trading on Friday.

Joint book-running managers Cowen and Company, JP…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.